Clinical Trial Update: Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC [Phase 2]

View source ↗

Summary

This update describes a Phase 2 clinical trial evaluating tislelizumab alone or with lenvatinib as neoadjuvant treatment for resectable recurrent hepatocellular…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Recurrent Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING